Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours

NCT00982865 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT00982865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00982865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2007
Completion date
April 30, 2016
Enrollment
182 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumors